Summit Therapeutics

Summit is a UK company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. Our strategy focuses on two therapy areas: Duchenne Muscular Dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria C. difficile.
Company Growth (employees)
Type
Public
HQ
Milton, GB
Founded
2003
Size (employees)
37 (est)+61%
Summit Therapeutics was founded in 2003 and is headquartered in Milton, GB

Summit Therapeutics Office Locations

Summit Therapeutics has offices in Milton, Cambridge
Milton, GB
Cambridge, US

Summit Therapeutics Metrics

Summit Therapeutics Summary

Market capitalization

£122.1 m

Closing share price

£2
Summit Therapeutics's current market capitalization is £122.1 m.

Summit Therapeutics Financials

Summit Therapeutics's revenue is £1.5 m in FY, 2016 which is a 32.4% decrease from the previous period.
FY, 2014FY, 2015FY, 2016

Revenue

£1.8 m£2.1 m£1.5 m

Revenue growth, %

16.5%(32.4%)

Summit Therapeutics Market Value History

We estimate that Summit Therapeutics's current employees are approximately 25% female and 75% male.

Summit Therapeutics Online Presence

Summit Therapeutics News

Summit Therapeutics Company Life

You may also be interested in